SRRA - Sierra Oncology raises additional funds from underwriters of stock offering

Sierra Oncology (NASDAQ:SRRA) said the underwriters of its previously announced public offering exercised in full their option to buy an additional 750K common shares at $27 per share. With this exercise, the gross proceeds to Sierra were ~$155.3M. Sierra intends to use the net proceeds to prepare for potential commercialization of momelotinib, clinical development of other product candidates, for research, working capital, and other general corporate purposes. SRRA +0.20% after hours to $29.36

For further details see:

Sierra Oncology raises additional funds from underwriters of stock offering